Aripiprazole in anorexia nervosa and low‐weight bulimia nervosa: Case reports
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objective: There has been much interest in the use of atypical antipsychotics in anorexia nervosa (AN). However, newer, more weight‐neutral medications have not been studied in AN, and there are no reports of the use of antipsychotics in bulimia nervosa (BN). Method: We report on the treatment of eight patients (five with AN and three with BN) with aripiprazole for time periods of four months to more than three years. Results: All individuals had reduced distress around eating, fewer obsessional thoughts about food, weight and body image, significant lessening of eating‐disordered behaviors, and gradual weight restoration where appropriate. Depression, generalized anxiety, and cognitive flexibility improved as well. Discussion: In summary, these findings support the need to perform controlled trials of aripiprazole in AN and BN. © 2010 by Wiley Periodicals, Inc. (Int J Eat Disord 2011; 44:269–275)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurobiology of anorexia and bulimia nervosa
Kaye, W. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.037 · Cited by 625 · cited 1×
“There is considerable evidence that AN and BN individuals have disturbances in dopaminergic and serotonergic neurotransmission.(37,38) Thus, it is plausible that the efficacy of atypicals is due to their actions at serotonergic and dopaminergic receptors.”
Self-citationOlanzapine therapy in anorexia nervosa: psychobiological effects
Brambilla, F., Garcia, C. S., Fassino, S., Daga, G. A., Favaro, A., Santonastaso, P., Ramaciotti, C., Bondi, E., Mellado, C., Borriello, R., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328080ca31 · Cited by 156
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149 · cited 1×
“Atypical antipsychotic trial data for efficacy in difficult depressive and anxiety disorders has continued to mount.(31,32) In late 2007, the US Food and Drug Administration (FDA) approved aripiprazole for use as an augmenting agent in the treatment of unipolar, nonpsychotic depression, the first such indication of it…”
Randomized Controlled Trial of Olanzapine in the Treatment of Cognitions in Anorexia Nervosa
Mondraty, N., Laird Birmingham, C., Touyz, S., Sundakov, V., Chapman, L., & Beumont, P. (2005) · Australasian Psychiatry · doi:10.1080/j.1440-1665.2004.02154.x · Cited by 130
Cited by
Anorexia nervosa and obesity are associated with opposite brain reward response
Frank, G. K. W., Reynolds, J. R., Shott, M. E., Jappe, L., Yang, T. T., Tregellas, J. R., & O'Reilly, R. C. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.51 · Cited by 311
Canadian practice guidelines for the treatment of children and adolescents with eating disorders
Couturier, J., Isserlin, L., Norris, M., Spettigue, W., Brouwers, M., Kimber, M., McVey, G., Webb, C., Findlay, S., Bhatnagar, N., et al. (2020) · Journal of Eating Disorders · doi:10.1186/s40337-020-0277-8 · Cited by 215
Aigner, M., Treasure, J., Kaye, W., Kasper, S., & The WFSBP Task Force on Eating Disorders (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.602720 · Cited by 207
“Vandereycken and Pierloot (1982) report a double blind placebo controlled cross over study on pimozide (4 or 6 mg) combined with behaviour therapy in 18 patients with anorexia nervosa.”
BackgroundPsychopharmacological advances in eating disorders
Himmerich, H., & Treasure, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1383895 · Cited by 119
Metadata
- Authors
- Trunko, M. E., Schwartz, T. A., Duvvuri, V., & Kaye, W. H.
- Venue
- International Journal of Eating Disorders
- Publisher
- Wiley
- Published
- 2011-03-11
- Volume
- 44
- Issue
- 3
- Pages
- 269-275
- ISSN
- 0276-3478 (ISSN-L)
- 1098-108X
- OpenAlex
- W2150738348
- Cited by
- 59
- References
- 4
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aripiprazole in anorexia nervosa and low‐weight bulimia nervosa: Case reports. https://app.cochat.ai/papers/10.1002/eat.20807
- The paper
- Trunko, M. E., Schwartz, T. A., Duvvuri, V., & Kaye, W. H. (2011). Aripiprazole in anorexia nervosa and low‐weight bulimia nervosa: Case reports. International Journal of Eating Disorders. https://doi.org/10.1002/eat.20807
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.